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SUMMARY Hemangiomas of infancy are the most common benign 
tumors of childhood. They are composed of proliferating endothelial 
tumor cells and usually manifest as cutaneous birthmarks. In most 
cases, these tumors characteristically follow a natural course of 
regression. However, they can cause a tremendous amount of anxiety. 
Hemangiomas can threaten vital life processes if located in certain areas 
of the body. They may also be part of larger syndromes associated 
with high rates of life-changing morbidity and mortality. In all of these 
situations, hemangiomas are often referred due to the uncertainties that 
exist regarding the most efficacious diagnosis and management.
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tumors
INTRODUCTION 
 Cutaneous birthmarks are often the result of 
vascular tumors and malformations. Over the past 
several decades some of the underlying process-
es behind these lesions have been elucidated. In 
doing so, hemangiomas are now recognized as 
well-defined vascular tumors. However, misleading 
terms from the past are still used to describe them. 
These are often inaccurate and used interchange-
ably. Mulliken and Glowacki proposed a set of cri-
teria to differentiate vascular tumors and malforma-
tions that have gained wide acceptance (Tables 1 
and 2) (1). These have been modified over the past 
two decades to incorporate new information, and 
the International Society for the Study of Vascular 
Anomalies has recently acknowledged an updated 
version (Table 3) (2). These criteria provide a well-
defined foundation from which a clinician may study, 
diagnose, and accordingly treat these lesions.
 Hemangioma of infancy is the accepted term 
used to describe the most common benign tumor 
in children (3). In the past, it has been used care-
lessly to describe a variety of cutaneous birth-
marks. It should only be used for the entity dis-
cussed here (Tables 1 and 2). Culinary adjectives 
such as strawberry and cherry are sometimes 
used to further describe some hemangiomas, but 
are not particularly clear. Modifiers such as  con-
ventional ones characterize lesions with respect to 
their location at different depths of the skin. Sub-
types of hemangiomas have been documented, 
such as noninvoluting (4) and lobular capillary 
hemangiomas (5), but should be distinguished 
from the common, benign form that is the focus of 
this article. 
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EPIDEMIOLOGY
 Hemangiomas of infancy are apparent at birth 
in 1.0%-2.6% of term neonates, but the incidence 
may be as high as 10%-12% in white children as 
the proliferative phase progresses in the first year 
of life (6). They affect females more than males 
with a 3:1 ratio (7,8). Approximately 30% of these 
birthmarks are apparent while the infant is in the 
newborn nursery. Their frequency tends to be 
higher in infants who are preterm, weigh less than 
1500 g (7), or were subject to chorionic villus sam-
pling in utero (9). The incidence might be lower in 
children of African or Asian descent (3). Segmen-
tal hemangioma, a lesion with a plaque-like mor-
phology, is more common in Hispanic infants (10). 
In patients aged 2-6 years, hemangiomas may be 
encountered in the involutive phase. Complete in-
volution usually occurs by age 7-10, and they are 
uncommon in children older than this.
 Some patients may have multiple lesions oc-
curring all over the body. This occurs uncommonly, 
and is referred to as hemangiomatosis. It is ap-
parent at birth in 61% and by one month of age in 
86% of cases (11). The two major classifications 
of hemangiomatosis will be described later.
ETIOLOGY AND PATHOLOGY
 Hemangiomas result from abnormal changes 
in angiogenesis that lead to over-proliferation of 
vascular entities. There may be a complex inter-
play of angiogenic and angiostatic forces involved 
in both normal and pathologic processes that lead 
to their formation (12). At this time, however, fe-
tal vascular development remains poorly under-
stood. Angiogenic markers such as proliferating 
cell nuclear antigen, basic fibroblast growth fac-
tor (bFGF), vascular endothelial growth factor 
(VEGF), E-selectin, and type IV collagenase are 
found at increased levels during the proliferative 
phase (13-15). During the involutive phase, there 
is a subsequent decrease of angiogenic factors 
Table 1. Mulliken and Glowacki classification of vascular anomalies
Vascular tumors Vascular malformations
Proliferating hemangiomas Capillary malformations




Table 2. Distinguishing characteristics between vascular tumors and malformations
Vascular tumors Vascular malformations
Endothelial cell proliferation Normal endothelial cell cycle
40% present at birth 90% present at birth
Rapid postnatal growth, followed by involution Grow commensurately with child growth
Table 3. International Society for the Study of Vascular Anomalies classification
Vascular tumors Vascular malformations
Hemangiomas of infancy Capillary malformations (port-wine stain)
Rapidly involuting hemangioma Venous malformations
Noninvoluting hemangioma Lymphatic malformations
Kaposiform hemangioendothelioma Arterial malformations
Tufted angioma Mixed malformations
Pyogenic granuloma
Malignant endovascular papillary angioendothelioma 
(Dabska tumor)
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with a 5-fold increase in endothelial cell apoptosis 
(16). This increase in cell death may be significant 
in overcoming the proliferation of endothelial cells, 
and may mark the beginning of involution. These 
alterations in angiogenesis may account for the in-
creased vascular proliferation that occurs in hem-
angiomas.
 Antigens relatively unique to hemangiomas 
have been identified that are not found in normal 
skin or vascular entities such as pyogenic granu-
loma, granulation tissue, tufted angioma, kaposi-
form hemangioendothelioma, or vascular malfor-
mations (17). The glucose transporter GLUT1 is 
normally expressed in various cell types through-
out the body, but not the skin. GLUT1 was found 
in samples taken from hemangiomas during all 
stages of its natural course (18), and has been 
found to be specific for this cutaneous birthmark. 
Markers such as merosin, Lewis Y antigen, and 
Fcγ receptor are also tissue-specific (17). Curi-
ously, chorionic villi also share this constellation of 
antigens, giving rise to a hypothesis of placental 
origin for hemangiomas (17,19). 
 Most hemangiomas develop sporadically and 
are believed to be the result of developmental er-
rors that occur between the 4th and 10th week of 
gestation. One series noticed a higher concen-
tration of focal hemangiomas in the center of the 
face, an area that contains the highest density of 
embryonic fusion lines on the face (19). Rarely, 
they are inherited in an autosomal dominant fash-
ion with moderate to high rates of penetrance (20). 
One study suggests that the formation of heman-
giomas may be associated with mutational events 
that result in the loss of heterozygosity at a spe-
cific locus on chromosome 5 (21). Three genes in-
volved in angiogenesis map to this chromosomal 
region, namely fibroblast growth factor receptor-4, 
platelet derived growth factor receptor-beta, and 
fms-related tyrosine kinase-4 (22). 
 Microscopic examination of hemangioma tissue 
reveals proliferating groups of endothelial cells. 
During involution, these cells flatten, the vessel 
lumina dilate, and fibrous tissue is deposited. His-
tologic examination of residual tissue reveals few 
feeding and draining vessels in a dense stroma of 
collagen and reticulin fibers (1).
CLINICAL FEATURES AND 
CONSIDERATIONS
 The natural history of hemangiomas usually 
follows a predictable course (23). The proliferative 
phase usually begins at 3-6 months and is com-
plete by 9-12 months of age. Few remain stable 
in size and appearance from birth, and exhibit no 
proliferative phase. Involution typically begins by 
12-18 months of age, and progresses at a rate of 
about 10% per year (24). It is usually complete by 
age 7-10, at which time only 50% of patients will 
have completely normal appearing skin, the rest 
exhibiting some form of residuum.
 Hemangiomas are most commonly located on 
the head and neck (59%), followed by the trunk 
(24%), lower extremities (10%), and upper ex-
tremities (7%) (25). Most are less than 2.0 cm in 
diameter, but in some instances can cover large 
portions of the body. Approximately 30% of these 
lesions are developed at birth. One-half of infants 
have premonitory skin findings that range from hy-
popigmented to a “bruise-like” macule (26). The 
clinical appearance of developed hemangiomas 
varies with the location of the tumor within the skin. 
Superficial hemangiomas are situated in the su-
perficial dermis, and appear as bright-red, raised 
nodules. This appearance gave rise to the term 
strawberry hemangioma. Lesions located deep in 
the reticular dermis or subcutaneous fat appear as 
normal appearing skin overlying soft masses with 
a bluish tone (27). These have often been referred 
to as deep or cavernous hemangiomas. Cases 
with both superficial and deep elements have also 
been described (23).
 During the involutive phase, superficial hem-
angiomas transform from a “strawberry” appear-
ing neoplasm to a duller, gray one. The tumor 
becomes softer to palpation as the vascular ele-
ments are replaced by connective tissue. In most 
cases, the more superficial and centrally located 
elements will show signs of involution first. Simi-
larly, deep hemangiomas also tend to lose their 
pigmented appearance as they enter the involu-
tive phase.
 One half of involuted hemanigomas will display 
some form of residual scar (23,25). The other 50% 
may exhibit telangiactasias, localized atrophy and 
alopecia, or a hyperpigmented residuum. The tim-
ing of all of these changes and their ultimate ap-
pearance is, however, difficult to predict.
 Hemangiomatosis is a relatively rare entity that 
is characterized by multiple cutaneous tumors. Le-
sions of hemangiomatosis are usually bright red, 
as in solitary hemangiomas, but range anywhere 
in size from 2 mm to 2 cm (28,29). Diffuse neo-
natal hemangiomatosis is characterized by the 
aforementioned skin findings and coexisting vis-
ceral involvement (11,29-31). The most common 
site of involvement is the liver, although nearly any 
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organ may be involved. Patients may show signs 
of high-output congestive heart failure, hemor-
rhage from the gastrointestinal or respiratory tract, 
or signs of hepatic involvement such as increased 
abdominal girth, hepatomegaly or obstructive 
jaundice (28,31). These infants have a relatively 
poor prognosis. 
 Benign neonatal hemangiomatosis has only 
cutaneous involvement or asymptomatic visceral 
involvement. It is commonly associated with com-
plete resolution of physical findings by the age of 
3 (11,31). Patients who present with multiple le-
sions should have a thorough history and physical 
examination. Suspicious clinical findings should 
guide the appropriate imaging studies (32). Al-
though hemanigomas are most often benign and 
located on the skin, tumors in alternate sites may 
threaten vital life processes. These sites include 
the eye and the airways. 
 Hemangiomas are the most common orbital 
tumor of infancy, and may threaten the develop-
ment of the visual axis (29,33). Periocular tumors 
may impinge upon external structures of the eye, 
or may be located deep in the orbit, producing pro-
ptosis. They may become large enough to physi-
cally obstruct the visual system or place pressure 
on the cornea, especially when located on the 
upper eyelid (33). Because of the high rate of vi-
sual complications, infants with periocular tumors 
should be promptly referred to an ophthalmologist 
for evaluation.
 Laryngeal disease often causes stridor or croup-
like symptoms, and 50% of cases have concurrent 
dermatologic manifestations. One study found 
that 63% of children with a “beard-like” distribu-
tion of vascular tumors had simultaneous airway 
hemangiomas (34). Respiratory symptoms should 
be evaluated in any infant with hemangiomatous 
disease in such a distribution.
 Hemangiomas may also be a part of a con-
stellation of associated anomalies termed the 
PHACE(S) syndrome. One should search for fea-
tures of this syndrome that includes posterior fos-
sa malformations, arterial anomalies, coarctation 
of the aorta, cardiac defects, eye abnormalities, 
and sternal defects (35-37). 
DIFFERENTIAL DIAGNOSIS
 The defining feature of hemangiomas is their 
natural course of proliferation and subsequent in-
volution. Upon initial presentation of a patient with 
vascular tumor-like lesion, one must also consider 
vascular malformations, noninvoluting heman-
giomas (4), lobular capillary hemangiomas (5), 
Dabska tumors (38), tufted angiomas, port-wine 
stains, or fibrosarcoma.
EVALUATION
 The diagnosis of a vascular tumor is based on 
history and physical examination alone in about 
95% of cases (39). Laboratory tests are not indi-
cated for the common cutaneous lesion, but may 
be performed in situations that have concurrent 
gastrointestinal or respiratory manifestations. 
 When the history and physical examination are 
equivocal, imaging studies are sometimes utilized 
to distinguish hemangiomas from other entities 
mentioned in the differential diagnosis. Distinct 
criteria are being developed that will allow the 
physician to diagnose an atypical lesion on mag-
netic resonance imaging (MRI) (40). This imag-
ing modality is of limited value unless contrast is 
used (40). MRI also allows for precise localization 
of the lesion, and can detect associated nervous 
system abnormalities. Ultrasound with Doppler in-
terrogation is the most cost-effective and noninva-
sive imaging technique (41). Results are operator 
dependent, and ultrasound does not illustrate the 
lesion relationship to other structures. These char-
acteristics make ultrasound suitable for following 
the course of internal lesions. Tissue biopsy is di-
agnostic, but high risk of bleeding makes this a 
somewhat unpopular method of diagnosis. It may 
be used to differentiate atypical hemangiomas 
from other soft-tissue tumors such as kaposiform 
hemangioendothelioma, myofibromatosis, and 
rhabdomyosarcoma (39).
MANAGEMENT AND TREATMENT
 The goals of management are to prevent or 
avoid life- or function-threatening complications, 
to prevent permanent disfigurement, to minimize 
the psychological impact on the patient and his/
her parents, to avoid aggressive or scarring treat-
ments, and to avoid/treat ulceration to minimize 
pain or scarring (39). Most hemangiomas of infan-
cy involute without intervention and are in anatom-
ically benign locations (24). It is therefore impor-
tant to educate parents about their child’s condi-
tion and describe its typical course, but also men-
tion that the rate of involution and the nature of the 
residuum might be unpredictable. This may ease 
anxiety if the lesion grows in the early stages. With 
effective patient education, one can avoid being 
pressured into instituting hasty medical therapy 
that may lead to a less desirable outcome. Regu-
lar follow up visits should be scheduled to monitor 
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the course of the lesion and to provide continuous 
reassurance. Second opinions from other physi-
cians may also be helpful. Parent education has 
been shown to significantly alleviate stress caused 
by hemangiomas and is a crucial part of treatment 
(42). 
MEDICAL THERAPY
 Early medical intervention is indicated when 
hemangiomas are located in areas that hinder 
normal development, interfere with vital life pro-
cesses, or cause severe pain (3,33,34,39). These 
locations include the eye, nose and airways. An-
other indication is a large facial lesion, since these 
almost inevitably will leave highly visible involutive 
scars. 
 Systemic glucocorticoids have been considered 
first-line therapy for severely deforming or life-
threatening lesions for several decades (39,43-
45). Recent reviews have reported efficacy rates of 
84% in infants treated with prednisone equivalent 
doses of 2.9 mg/kg when administered during the 
proliferative phase (45). Doses of 2 to 4 mg/kg in a 
single morning or divided dose have been recom-
mended, with larger doses being used for tumors 
that compromise the airways (39). Complications 
have been reported in approximately 35% of pa-
tients, with no catastrophic results (45,46). Com-
mon side effects such as irritability, cushingoid 
appearance, and adrenal suppression are tem-
porary. Bacterial infection secondary to immune 
suppression is uncommon (46). To avoid adrenal 
crisis, steroids should not be stopped abruptly and 
the patient will require stress doses for months fol-
lowing treatment.
 The use of intralesional triamcinolone in treat-
ing problematic cases was first demonstrated in 
the treatment of periorbital hemangiomas (39). Its 
effectiveness in treating localized cutaneous hem-
angiomas has since been demonstrated (47). One 
therapeutic regimen entails multiple injections of a 
50:50 mix of triamcinolone (40 mg/mL) and beta-
methasone (6 mg/mL) at doses of 3-5 mg/kg per 
treatment every four to six weeks (48,49). Com-
plications are relatively rare. An ophthalmologist 
should evaluate orbital hemangiomas.  
 Interferon alfa-2a is used for life-threatening or 
deforming hemangiomas that have not responded 
to glucocorticoid therapy (50-52). This treatment 
is administered subcutaneously at a dose of 1 
to 3 million U per square meter of body surface 
area. Common side effects include fever, malaise, 
neutropenia and elevated liver enzymes (50-53). 
One series reported on 100% of patients exhibit-
ing some degree of toxicity (53). Interferon is not 
regularly used due to its potential for neurotoxic-
ity (53). The spectrum of neurologic side effects 
ranges from agitation and irritability to seizure and 
permanent spastic diplegia (53,54). 
 Newer laser treatments have rapidly risen to 
the forefront of the hemangioma management 
due to their safety and efficacy (39,55). With re-
cent technological innovations, the flash-lamp, 
pumped, pulse-dye laser (FPDL) is considered the 
most effective laser treatment for superficial hem-
angiomas and residual lesions (39,55). The FPDL 
produces short pulses of light at 585 nm, and the 
typical time of exposure is 0.45 ms (39,56-58). 
For proliferating lesions, treatments are spaced 
at 2- to 3-week intervals, and at 4 to 6 weeks for 
nonproliferative lesions (59). Atrophic scarring is 
less common than with argon laser, still producing 
side effects (56,60). The FPDL, however, is limited 
by its depth of penetration, and is ineffective on 
deep hemangiomas (55,57,58,61). The neodym-
ium:yttrium-aluminum-garnet laser has produced 
promising results in deep hemangiomas (54,61). 
Treating uncomplicated hemangiomas with the 
FPDL has yet to be proven more effective than 
the conservative approach (56). New generations 
of FPDLs that are less painful are currently being 
studied (63). For now, clear indications for early 
laser treatment remain ulcerated lesions after topi-
cal therapies have failed, and residual telangiecta-
sias (3,39,57).
 Local wound care for alleviation of pain and re-
duction of infection rate has been the foundation 
for treatment of ulcerated lesions (3,64-66). Ulcer-
ation affects between 5% and 15% of hemangio-
mas, and is the most frequent complication (64,65). 
Along with infection, ulceration can lead to disfig-
urement and pain. Compresses are a readily avail-
able measure that can be used to debride the ulcer 
(3,64,65), and can be used in conjunction with topi-
cal mucoprin, bacitracin, or metronidazole (64).
SURGICAL THERAPY
 The technique and timing for surgical resection 
of hemangiomas is still a topic of contentious de-
bate. The surgeon must identify situations where 
an excision procedure will produce a more cos-
metically acceptable result than conservative or 
medical treatment. The timing of resection is also 
a factor since facial deformities can have a psy-
chological impact on children, especially when 
they enter their school-age years. Some still advo-
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cate postponing excision until after the involution 
phase. Specific situations where surgical inter-
vention is indicated include abnormal scar or ex-
cess tissue following natural involution, ulcerated 
lesions that bleed excessively or are associated 
with pain, and lesions that interfere with the de-
velopment and/or activities necessary for life in-
cluding vascular tumors of the eye, ear, or larynx 
(33,34,39,64,65,67-70). One study evaluated the 
outcome of a circular excision with purse-string 
closure using a single 4-0 or 5-0 suture versus a 
standard lenticular excision (67). Circular excision 
resulted in an average scar that was 15% of its 
original area. In addition, the scar length with cir-
cular excision was by 72% shorter than with len-
ticular excision. There was no significant variation 
between the phase in which the procedure was 
performed. There was no variation in the result if 
the circular or lenticular excision was performed 
as a follow-up procedure to further reduce the scar 
size either. To date, no other excision and closure 
technique results in a smaller scar.  
CONCLUSIONS
 Hemangiomas are rather unsightly lesions, and 
parents of these children, understandably, will of-
ten pressure physicians to deliver definitive medi-
cal or surgical treatment. The physician should be 
well versed in the natural history of the lesion, the 
risks and benefits of available treatment modalities, 
and educate parents to alleviate the psychologi-
cal stress placed upon the family. One should be 
concerned if there are multiple tumors, periorbital 
lesions, signs of airway obstruction, or symptoms 
of visceral hemangiomas. Better understanding of 
these lesions and new generations of the FPDL 
may soon lead to effective early interventions for 
nonproblematic lesions. For now, the physician 
should provide ongoing assurance that the child is 
healthy, and that the appearance of the lesion will 
improve with time.
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